Nano-salbutamol dry powder inhalation: A new approach for treating broncho-constrictive conditions

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 71, Issue 2, 2009, Pages 282-291

  Bhavna, ^a   Ahmad, Farhan Jalees ^a   Mittal, Gaurav ^b   Jain, Gaurav K ^a   Malhotra, Geena ^c   Khar, Roop K ^a   Bhatnagar, Aseem ^b  

^a HAMDARD UNIVERSITY   (India)

^b INSTITUTE OF NUCLEAR MEDICINE AND ALLIED SCIENCES   (India)

^c CIPLA LTD   (India)

Author keywords

Anti solvent precipitation; Inhalation; Lung deposition; Nano sizing; Salbutamol sulphate; Spray drying

Indexed keywords

LACTOSE; NANOPARTICLE; SALBUTAMOL; TECHNETIUM 99M;

ADULT; ARTICLE; BRONCHOSPASM; DRUG BIOAVAILABILITY; DRUG FORMULATION; DRY POWDER; FEMALE; HUMAN; MALE; NORMAL HUMAN; PARTICLE SIZE; PRECIPITATION; SOLID;

ADMINISTRATION, INHALATION; ADULT; ALBUTEROL; BIOLOGICAL AVAILABILITY; BRONCHODILATOR AGENTS; DRUG DELIVERY SYSTEMS; EXCIPIENTS; FEMALE; HUMANS; LACTOSE; LUNG; MALE; MIDDLE AGED; NANOPARTICLES; NEBULIZERS AND VAPORIZERS; PARTICLE SIZE; POWDERS; RADIOPHARMACEUTICALS; TECHNETIUM; TISSUE DISTRIBUTION; YOUNG ADULT;

EID: 59649084577     PISSN: 09396411     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejpb.2008.09.018     Document Type: Article

References (34)

1. Braganza G., and Thomson N.C. Acute severe asthma in adults. Adult Asthma (2008) 209-212
2. Khaltaev N., Minelli E., and Desloovere P. Global alliance against chronic respiratory diseases (GARD): a world where all people breathe freely. Revue française d'allergologie et d'immunologie clinique 47 (2007) 246-247
3. Boltea R.G. Emergency department management of pediatric asthma. Clin. Pediatric Emerg. Med. 5 4 (2004) 256-269
4. Georgitis J.W. The 1997 Asthma management guidelines and therapeutic issues relating to the treatment of asthma. Chest 115 (1999) 210-217
5. Newhouse M.T., and Corkery K.J. Aerosols for systemic delivery of macromolecules. Respir Care Clin. N. Am. 7 (2001) 261-275
6. Bennett W.D., Brown J.S., Zeman K.L., Hu S.C., Scheuch G., and Sommerer K. Targeting delivery of aerosols to different lung regions. J. Aerosol Med. 15 (2002) 179-188
7. Dhand R. Future directions in aerosol therapy. Respir. Care Clin. N. Am. 7 (2001) 319-335
8. Schurch S., Gehr P., Hof V.I., Geiser M., and Green F. Surfactant displaces particles towards the epithelium in airways and alveoli. Respir. Physiol. 80 (1990) 17-32
9. Caramori G., and Adcock I. Pharmacology of airway inflammation in asthma and COPD. Pulmonary Pharmacol. Ther. 16 (2003) 247-277
10. Young P.M., Cocconi D., Colombo P., Bettini R., Price R., Steele D.F., and Tobyn M.J. Characterization of a surface modified dry powder inhalation carrier prepared by "particle smoothing". J. Pharm. Pharmacol. 54 10 (2002) 1339-1344
11. Wedaa M., Zanenb P., de Boerc A.H., Barendsa D.M., and Frijlinkc H.W. An investigation into the predictive value of cascade impactor results for side effects of inhaled Salbutamol. Int. J. Pharm. 287 1-2 (2004) 79-87
12. Johnson K.A. Preparation of peptide and protein powders for inhalation. Adv. Drug Deliv. Rev. 26 (1997) 29-40
13. Schulz H. Mechanisms and factors affecting intrapulmonary particle deposition: implications for efficient inhalation therapies. Pharm. Sci. Technol. Today 1 (1998) 336-344
14. Bondesson E., Bengtsson T., Borgstrom L., Nilsson L.-E., Norrgren K., Trofast E., and Wollmer P. Planar gamma scintigraphy-points to consider when quantifying pulmonary dry powder aerosol deposition. Int. J. Pharm. 251 (2003) 33-47
15. Sung J.C., Pulliam B.L., and Edwards D.A. Nanoparticles for drug delivery to the lungs. Trends Biotechnol. 25 12 (2007) 563-570
16. Kreuter J. Drug targeting with nanoparticles. Eur. J. Drug Metab. Pharmacol. 19 (1994) 253-256
17. Couvreur P., and Vauthier C. Polyalkylcyanoacrylate nanoparticles as drug carrier: present state and perspectives. J. Control. Release 17 (1991) 187-198
18. Kreuter J. Nanoparticle-based drug delivery systems. J. Control. Release 16 (1991) 169-176
19. Shekunov B.Y., Chattopadhyay P., Tong H.H.Y., and Chow A.H.L. Particle size analysis in pharmaceutics: principles, methods and applications. Pharm. Res. 24 (2007) 203-226
20. Fels A.O., and Cohn Z.A. The alveolar macrophage. J. Appl. Physiol. 60 (1986) 353-369
21. Edwards D.A., et al. Recent advances in pulmonary drug delivery using large, porous inhaled particles. J. Appl. Physiol. 85 (1998) 379-385
22. Oberdorster G., et al. Nanotoxicology: an emerging discipline evolving from studies of ultrafine particles. Environ. Health Perspect. 113 (2005) 823-839
23. G. Mittal, T. Singh, N.C. Gooomer. A. Bhatnagar, A. Lulla, G. Malhotra, R. Kashyap, R.P. Tripathi, Formulations and methods thereof for making Radiolabeled Dry Powder, Patent No. 1536/DEL/2008.
24. Pilcer G., Goole J., Gansbeke B.V., Blocklet D., Knoop C., Vanderbist F., and Amighi K. Pharmacoscintigraphic and pharmacokinetic evaluation of tobramycin DPI formulations in cystic fibrosis patients. Eur. J. Pharm. Biopharm. 68 (2008) 413-421
25. M. Bhavna, F.J. Ahmad, R.K. Khar, S. Sultana, A. Bhatnagar, Techniques to develop and characterize nanosized formulation for salbutamol sulfate, J Mater Sci Mater Med. 10 June 2008 [Epub ahead of print].
26. Newman S.P., Clark A.R., Talalee N., and Clarke S.W. Pressurised aerosol deposition in the human lung with and without an open spacer. Thorax 44 (1989) 706-710
27. Borgstrom L., Bondesson E., Moren F., Trofast E., and Newman S.P. Lung deposition of budesonide inhaled via Turbuhaler: a comparison with terbutaline sulphate in normal subjects. Eur. Respir. J. 7 (1994) 69-73
28. Usmani O.S., Biddiscombe M.F., and Barnes P.J. Regional lung deposition and bronchodilator response as a function of beta2-agonist particle size. Am. J. Resp. Crit. Care Med. 172 (2005) 1497-1504
29. Nazir J., Barlow D.J., Lawrence M.J., Richardson C.J., and Shrubb I. Artificial neural network prediction of aerosol deposition in human lungs. Pharm. Res. 19 8 (2002) 1130-1136
30. Nazir J., Lawrence M.J., and Shrubb I. Artificial neural network prediction of the patterns of deposition of polydisperse aerosols within human lungs. J. Pharm. Sci. 94 9 (2005) 1986-1997
31. Schiavone H., Palakodaty S., Clark A., York P., and Tzannis S.T. Evaluation of SCF-engineered particle-based lactose blends in passive dry powder inhalers. Int. J. Pharm. 281 (2004) 55-66
32. Podczeck F. The influence of particle size distribution and surface roughness of carrier particles on the in vitro properties of dry powder inhalations. Aerosol Sci. Tech. 31 (1999) 301-321
33. Nantel N., and Newhouse M.T. Inspiratory flow rates through a novel dry powder inhaler (Clickhaler) in pediatric patients with Asthma. J. Aerosol Med. 12 2 (1999) 55-58
34. Williams III R.O., Brown J., and Liu J. Influence of micronization method on the performance of a suspension triamcinolone acetonide pressurized metered-dose inhaler formulation. Pharm. Dev. Technol. 4 2 (1999) 167-169